Literature DB >> 7889816

[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].

R J Adamek1, C Szymanski, B Pfaffenbach, W Opferkuch, D Ricken, M Wegener.   

Abstract

In a prospective study 27 patients (13 women, 14 men; mean age 62 [45-83] years) with Helicobacter (H.) pylori associated disease received over 7 days pantoprazole (40 mg twice daily), clarithromycin (500 mg twice daily) and metronidazole (500 mg twice daily). Six patients had gastric ulcer, 4 duodenal ulcer, 4 erosive gastritis, 6 erosive duodenitis and 7 had H. pylori-positive functional dyspepsia. Pre-treatment oesophago-gastro-duodenoscopy was combined in 4 patients with antral and in 4 others with body-of-stomach biopsies to demonstrate H, pylori (urease test, specific culture and histology). The H. pylori status was checked with the 13C-urea breath test 4 weeks after the end of treatment. In addition, 9 patients with peptic ulcer were examined endoscopically at least 2 weeks after onset of the treatment to check for any healing of the ulcers, 25 of the patients completed the study according to the protocol. The H. pylori eradication rate was 100% (25 of 25 patients), while the "intention to treat" analysis gave a rate of 92.6% (25 of the 27 patients). The peptic ulcers were found to be healed in all 9 patients who had been endoscoped. One woman developed a reversible stomatitis, but the drug treatment did not have to be stopped. -These findings indicate that short-term triple treatment in the described manner is efficacious in curing H. pylori infection and any peptic ulcer. It is thus a highly promising treatment of H. pylori-associated diseases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7889816     DOI: 10.1055/s-2008-1055353

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  6 in total

Review 1.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

3.  [Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].

Authors:  J Glaser; J Hein; R Daikeler; G Weithofer; M Vieth; M Schmidt; M Stolte
Journal:  Med Klin (Munich)       Date:  1998-02-15

Review 4.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 5.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

6.  Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy?

Authors:  Asad I Dajani; Adnan M Abu Hammour; Ding H Yang; Peter C Chung; Mohammed A Nounou; KaiTao Y Yuan; Mohammed A Zakaria; Hanping S Schi
Journal:  Saudi J Gastroenterol       Date:  2013 May-Jun       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.